ARTICLE | Management Tracks
Plus: Nurix appoints Julia Gregory as chair, and updates from Valneva, Alto, Cour and Kronos
By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
May 22, 2024 12:13 AM UTC
Eden Wells will lead a new division at the U.S. unit of Novartis AG (SIX:NOVN; NYSE:NVS) as chief insights and decision science officer. Wells, who joined the Swiss pharma in 2019 as VP, head of patient and specialty services, was most recently chief patient experience officer. The new division will use AI and advanced analytics to understand how human behavior impacts care decisions, outcomes and delivery.
David Lacey stepped down as chair of Nurix Therapeutics Inc. (NASDAQ:NRIX), which is developing targeted protein modulation drugs. Lacey will remain on the board and is succeeded as chair by Julia Gregory, chair and CEO of advisory firm Isometry Advisors Inc…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652484/eden-wells-to-lead-insights-and-decision-science-at-novartis